Abivax Posts 2025 Results, Confirms Phase 3 Ulcerative Colitis Timeline and Expands Leadership Team

An update from Abivax SA Sponsored ADR ( (ABVX) ) is now available.

Abivax reported its audited full-year 2025 financial results on March 23, 2026, highlighting a July 28, 2025 U.S. offering that raised about €597.2 million and a year-end cash, cash equivalents and short-term investment balance of €530.4 million, providing runway into the fourth quarter of 2027. The company sharply increased R&D spending to €177.8 million, mainly to advance obefazimod in ulcerative colitis, Crohn’s disease and new indications, while also settling all outstanding debt facilities and senior convertible notes.

Operating expenses shifted with G&A costs more than doubling to €67.7 million in 2025 due largely to higher personnel-related charges linked to share price gains, while sales and marketing expenses eased to €5.2 million after one-off rebranding costs in 2024. The financial profile underscores Abivax’s deliberate investment in late-stage development and organizational build-out ahead of potential commercialization.

On the clinical front, an independent Data Safety Monitoring Board review on March 18, 2026 for the pivotal Phase 3 ABTECT-UC maintenance trial found no new safety signals, with nearly 90% of patients having completed 44 weeks of treatment. The program remains on schedule to deliver topline Phase 3 maintenance data in late second quarter 2026, an anticipated inflection point for obefazimod and for Abivax’s positioning in the ulcerative colitis landscape.

Abivax also announced leadership changes and governance updates, including the March 19, 2026 departure of Sofinnova Partners’ representative from the board and the appointments of Michael Nesrallah as Chief Commercial Officer, Keith Fournier as Senior Vice President of Global Regulatory Affairs, and Maurus de la Rosa as Senior Vice President of Research. These hires bring deep commercial, regulatory and scientific experience in gastroenterology, immunology and advanced therapies, and are intended to support regulatory filings, launch readiness and long-term growth as the company prepares for possible market entry of obefazimod.

Looking ahead, Abivax has scheduled its Annual General Meeting for May 11, 2026 and plans to report first-quarter 2026 financial results on May 25, 2026, milestones that will follow closely on the expected ABTECT-UC topline data release. Together, the strengthened balance sheet, de-levered capital structure, positive safety update and expanded leadership bench illustrate a company transitioning from a pure development focus toward a potential commercial-stage profile in inflammatory bowel disease.

The most recent analyst rating on (ABVX) stock is a Buy with a $170.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.

Spark’s Take on ABVX Stock

According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.

The score is primarily held down by weak financial performance—ongoing losses, negative operating cash flow, and reliance on financing with high leverage. Technicals offer only moderate support with a longer-term uptrend but weaker near-term momentum, while valuation lacks support due to negative earnings and no dividend yield.

To see Spark’s full report on ABVX stock, click here.

More about Abivax SA Sponsored ADR

Abivax SA is a clinical-stage biotechnology company headquartered in Paris that develops therapeutics designed to harness the body’s natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Its lead product candidate is obefazimod, which is being advanced in Phase 3 trials for moderately to severely active ulcerative colitis and in Phase 2b studies for Crohn’s disease, positioning the company in the inflammatory bowel disease market.

Average Trading Volume: 1,217,834

Technical Sentiment Signal: Hold

Current Market Cap: $10.01B

Learn more about ABVX stock on TipRanks’ Stock Analysis page.